The mRNA expression of an array of heterotypic biomarkers may explain the course of this patient's clinical outcome as gene expression indicates the participation of unique cancer-related transcripts specifically related to GBM stem cells, such as caveolin-1 and −2. This evidence concerns the gene CAV1 and cancer.